Scynexis, Inc.

GSK’s gepotidacin has been put on the regulatory fast track in the US, raising hopes that it could be the first in a new class of oral antibiotic treatment for uncomplicated urinary tract infections (

The Biotech Patient In one of David Poyer’s novels on the career of a fictional US naval officer, a regional war erupts and politicians consult with academics on how such conflicts are resolved. While

A beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic

F2G Ltd encountered a significant setback as the US Food and Drug Administration gave the firm a complete response letter (CRL) for olorofim in invasive fungal infections. F2G said it is confident it